A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With
Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With
Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone
(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received
at Least 1 Prior Line of Therapy
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
